Table 4.
Summary of patients reporting any health problem by EQ-5D domain in the PILLAR and ASPIRE studies
| EQ-5D domain | Study visit | PILLAR, n/N (%) | ASPIRE, n/N (%) | ||
|---|---|---|---|---|---|
| All simeprevir | Placebo/PR | All simeprevir | Placebo/PR | ||
| Mobiity | Baseline | 21/306 (6.9) | 5/77 (6.5) | 27/386 (7.0) | 6/64 (9.4) |
| Week 24 | 61/285 (21.5) | 6/72 (8.3) | 80/355 (22.6) | 14/51 (27.5) | |
| Week 48 | 25/271 (9.3) | 11/67 (16.4) | 76/352 (21.6) | 11/55 (20.0) | |
| Week 72 | 16/279 (5.7) | 5/68 (7.4) | 38/340 (11.2) | 11/55 (20.0) | |
| Self-care | Baseline | 3/306 (1.0) | 2/77 (2.6) | 5/387 (1.3) | 2/64 (3.1) |
| Week 24 | 6/285 (2.1) | 2/72 (2.8) | 13/354 (3.7) | 3/51 (5.9) | |
| Week 48 | 5/271 (1.9) | 2/68 (2.9) | 18/352 (5.1) | 5/55 (9.1) | |
| Week 72 | 6/279 (2.2) | 1/68 (1.5) | 9/339 (2.7) | 3/55 (5.5) | |
| Usual activities | Baseline | 32/305 (10.5) | 4/77 (5.2) | 49/387 (12.6) | 9/64 (14.1) |
| Week 24 | 148/284 (52.1) | 36/72 (50.0) | 159/354 (44.9) | 18/51 (35.3) | |
| Week 48 | 46/271 (17.0) | 31/68 (45.5) | 153/351 (43.6) | 17/55 (30.9) | |
| Week 72 | 36/279 (12.9) | 8/68 (11.8) | 55/338 (16.3) | 12/55 (21.8) | |
| Pain/discomfort | Baseline | 83/306 (27.1) | 17/77 (22.1) | 109/385 (28.3) | 15/64 (23.4) |
| Week 24 | 154/285 (54.0) | 45/72 (62.5) | 193/354 (54.5) | 21/51 (41.2) | |
| Week 48 | 73/271 (27.0) | 38/68 (55.9) | 188/349 (53.9) | 22/55 (40.0) | |
| Week 72 | 64/279 (23.0) | 19/68 (27.9) | 107/337 (31.8) | 21/55 (38.2) | |
| Anxiety/ | Baseline | 71/306 (23.2) | 15/77 (19.5) | 80/385 (20.8) | 11/64 (17.2) |
| depression | Week 24 | 130/284 (45.7) | 39/72 (54.2) | 165/355 (46.4) | 21/51 (41.2) |
| Week 48 | 65/271 (23.9) | 24/68 (35.3) | 168/351 (47.9) | 20/55 (36.4) | |
| Week 72 | 63/279 (22.6) | 15/68 (22.0) | 94/338 (27.9) | 18/55 (32.7) | |
EQ-5D European Quality of Life 5-Dimensions, PR placebo/peginterferon-α and ribavirin.